The harsh reality of weight-loss drugs: When you stop, the weight often comes back. A recent analysis published in the BMJ reveals a concerning pattern: stopping weight-loss medications can lead to rapid weight regain and a loss of the health benefits gained. This is a critical issue as more people turn to these drugs.
Researchers from the University of Oxford discovered that individuals regained an average of 0.4 kg per month after discontinuing weight-loss medications. Modeling suggests that all lost weight is likely to be regained within 1.7 years. Furthermore, improvements in health markers like blood pressure, cholesterol, and diabetes risk were projected to revert to pre-treatment levels within 14 months.
Interestingly, weight regain happened nearly four times faster after stopping medication compared to stopping lifestyle programs focused on diet and exercise, regardless of initial weight loss.
This raises significant questions, especially with the growing use of GLP-1 receptor agonists in primary care.
"From a behavioural science perspective, this review highlights a key limitation of relying on weight management medications as a stand-alone strategy," explains Associate Professor Dominika Kwasnicka, a behavioral scientist from the University of Melbourne. She notes that while these medications can be effective, obesity is a chronic condition shaped by behaviors, environment, and ongoing support. Medications primarily affect biological pathways, but don't establish the changes needed for lasting weight loss.
But here's where it gets controversial... Professor Kwasnicka highlights the policy implications, especially in Australia, where access to these medications is expanding, often with substantial out-of-pocket costs and limited follow-up care. Without long-term planning, there's a risk of short-term gains followed by weight regain. She emphasizes the need for comprehensive care models that include behavioral support and realistic treatment duration discussions, rather than viewing these medications as quick fixes.
Highly effective medications, like semaglutide and tirzepatide (GLP-1 RAs), have revolutionized obesity care, enabling significant weight loss and short-term metabolic health improvements. However, real-world data indicates that around half of patients discontinue GLP-1 RA therapy within 12 months, often due to cost, side effects, or the expectation of short-term treatment.
The analysis examined 37 studies published up to February 2025, involving 9341 adults. The studies compared weight-loss medications with placebos or non-drug behavioral interventions. The average treatment duration was 39 weeks, with a mean follow-up of 32 weeks after treatment ended.
The authors conclude that the evidence cautions against short-term use and emphasizes the need for strategies to support long-term weight control. They stress that medication alone isn't enough for sustained benefit, and primary prevention remains critical.
"As obesity is a chronic and relapsing condition, prolonged treatment with WMM [weight management medications] may be required to sustain the health benefits," the researchers wrote. One trial showed successful weight loss maintenance over four years with continuous semaglutide treatment. In the USA and Denmark, discontinuation rates outside of clinical trials are around 50% at one year.
In a linked editorial, Associate Professor Qi Sun from Harvard Medical School, casts doubt on the idea that GLP-1 receptor agonists are a definitive cure for obesity. He argues that patients should be informed about high discontinuation rates and the metabolic consequences of stopping therapy. Healthy dietary and lifestyle practices should remain the foundation of obesity management, with medications used as adjuncts.
"The results are not surprising given that it is well-documented that reduced adherence to, or cessation of, dietary and lifestyle interventions leads to similar patterns of weight regain," Professor Sun wrote.
He suggests switching to healthy diets and lifestyles that have been proven effective in preventing excess weight regain.
Professor John B Dixon from Swinburne University of Technology, Melbourne, agrees, stating that these new medications have improved efficacy but don't cure the underlying issue of disordered energy balance.
What are your thoughts? Do you think the current approach to weight-loss medication adequately addresses the need for long-term support? Share your perspective in the comments below!
